GSK's 2024 results are strong, with a promising shift toward specialty medicines, particularly in HIV, respiratory conditions, and cancer, driving long-term growth. Key drugs Blenrep and Depemokimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results